OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

CEO exercised or converted 17K HALO derivative securities | OQRO

Home
Insider trades
Halozyme
CEO exercised or converted 17K HALO derivative securities

Insider trades

Insider trade

CEO exercised or converted 17K HALO derivative securities

Traded Dec 1, 2025 · Filed Dec 2, 2025

HalozymeHALO

17K
Shares · @ $8.11

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 1, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 2, 2025

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001159036-25-000063

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Dec 2, 2025, 12:31 AM UTC

Added to OQRO

Oct 6, 2026, 7:59 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

HALOZYME THERAPEUTICS, INC.

Issuer CIK

1159036

Ticker

HALO

Reporting person

Helen Torley

Relationship

Director, Officer

Officer title

PRESIDENT AND CEO

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Dec 1, 2025

Transaction code

Shares / units

16,569

Price per share

$8.11

Acquired / disposed

Acquired (A)

Shares owned after

725,288

Ownership form

Direct

Amendment

Footnotes from the filing

The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026.